T2 Biosystems, Inc. (TTOO) | Investment Case

1. Company Snapshot

1.a. Company Description

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally.Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus.

In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease.The company has collaboration agreements with Canon U.S. Life Sciences, Inc.to develop a diagnostic test panel to detect Lyme disease.

T2 Biosystems, Inc.was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Show Full description

1.b. Last Insights on TTOO

T2 Biosystems' recent performance was impacted by lackluster investor sentiment. The company's shares crossed above its 50-day moving average, but trading volume remained low, with only 10,180 shares changing hands. A recent report raised questions about the stock's future prospects. Furthermore, scrutiny around the company's financials and operations may be intensifying. Notably, no updates on share buybacks or new product launches were disclosed. The last reported data showed a 50-day moving average of $0.01.

1.c. Company Highlights

Last Price	0.0
Change Percentage	36.36%
Open	0.0
Previous Close	0.0
Market Cap ( Millions)	0
Volume	588
Year High	0.18
Year Low	0.0
M A 50	0.0
M A 200	0.03

FCF Yield	-78327.39%
Dividend Yield	0.00%
ROE	147.27%
Debt / Equity	-176.55%
Net Debt / EBIDTA	-77.06%
Price To Book	-0.0
Price Earnings Ratio	-0.0
Price To FCF	-0.0
Price To sales	0.01
EV / EBITDA	-0.77

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Reviewing T2 Biosystems (NASDAQ:TTOO) & Acutus Medical (NASDAQ:AFIB)

Feb -19

Source: defenseworld.net

T2 Biosystems (NASDAQ:TTOO) Shares Cross Below Two Hundred Day Moving Average – Should You Sell?

Jan -24

Source: defenseworld.net

T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review

Jan -10

Source: defenseworld.net

T2 Biosystems (NASDAQ:TTOO) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened

Dec -27

Source: defenseworld.net

T2 Biosystems (NASDAQ:TTOO) Shares Cross Above 50 Day Moving Average – What’s Next?

Dec -03

Source: defenseworld.net

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

Dec -16

Source: globenewswire.com

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Dec -09

Source: globenewswire.com

T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript

Nov -14

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.11%)

6. Segments

Consumables

Expected Growth: 9.08%

T2 Biosystems' Consumables segment growth of 9.08% is driven by increasing adoption of sepsis diagnostics, expansion into new markets, and growing demand for rapid diagnostic testing. Additionally, the company's strategic partnerships and investments in product development have contributed to the growth, as well as the rising need for accurate and timely diagnosis in the healthcare industry.

Instruments

Expected Growth: 9.27%

T2 Biosystems' 9.27% growth is driven by increasing adoption of its sepsis diagnostic instruments, expansion into new markets, and growing demand for rapid diagnostic testing. The company's innovative T2Bacteria Panel and T2Candida Panel products are gaining traction, contributing to revenue growth. Additionally, strategic partnerships and investments in research and development are fueling the company's expansion.

Service

Expected Growth: 9.95%

T2 Biosystems' 9.95% growth is driven by increasing adoption of its sepsis diagnostic products, expansion into new markets, and growing demand for rapid diagnostic testing. The company's innovative T2Bacteria Panel and T2Candida Panel products are gaining traction, and its partnerships with hospitals and healthcare systems are contributing to revenue growth.

Contribution

Expected Growth: 10.33%

T2 Biosystems' 10.33% growth is driven by increasing adoption of its sepsis diagnostic products, expansion into new markets, and strategic partnerships. The company's innovative T2Bacteria Panel and T2Candida Panel have gained traction, leading to higher sales. Additionally, growing demand for rapid diagnostic testing and increasing awareness of sepsis diagnosis have contributed to the company's growth.

Instrument Rentals

Expected Growth: 8.4%

T2 Biosystems' Instrument Rentals growth of 8.4% is driven by increasing adoption of sepsis diagnostics, expansion into new geographies, and growing demand for rapid diagnostic solutions. Additionally, the company's strategic partnerships and investments in product development have enhanced its offerings, contributing to the segment's growth.

7. Detailed Products

T2Bacteria Panel

A diagnostic panel that detects and identifies sepsis-causing bacteria directly from whole blood

T2Candida Panel

A diagnostic panel that detects and identifies Candida species directly from whole blood

T2Resistance Panel

A diagnostic panel that detects genetic markers of antibiotic resistance directly from whole blood

T2SARS-CoV-2 Panel

A diagnostic panel that detects SARS-CoV-2 RNA directly from respiratory specimens

T2Dx Instrument

A diagnostic instrument that automates the T2 Biosystems' diagnostic panels

8. T2 Biosystems, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

T2 Biosystems, Inc. has a low threat of substitutes due to its unique diagnostic products and services, which are not easily replaceable by other products or services.

Bargaining Power Of Customers

T2 Biosystems, Inc. has a medium bargaining power of customers, as its customers have some negotiating power due to the availability of alternative diagnostic products and services.

Bargaining Power Of Suppliers

T2 Biosystems, Inc. has a low bargaining power of suppliers, as it has a diverse supplier base and is not heavily dependent on a single supplier.

Threat Of New Entrants

T2 Biosystems, Inc. has a high threat of new entrants, as the diagnostic industry is attractive and has low barriers to entry, making it easy for new companies to enter the market.

Intensity Of Rivalry

T2 Biosystems, Inc. operates in a highly competitive industry, with many established players, leading to a high intensity of rivalry among competitors.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	230.63%
Debt Cost	4.18%
Equity Weight	-130.63%
Equity Cost	4.18%
WACC	4.18%
Leverage	-176.55%

11. Quality Control: T2 Biosystems, Inc. passed 5 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Personalis

A-Score: 3.9/10

Value: 6.4

Growth: 3.1

Quality: 3.7

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

VolitionRx

A-Score: 3.7/10

Value: 8.0

Growth: 6.3

Quality: 5.8

Yield: 0.0

Momentum: 1.0

Volatility: 1.3

1-Year Total Return ->

Bionano Genomics

A-Score: 3.3/10

Value: 10.0

Growth: 4.3

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

T2 Biosystems

A-Score: 3.2/10

Value: 10.0

Growth: 4.7

Quality: 4.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Aclaris Therapeutics

A-Score: 3.2/10

Value: 6.7

Growth: 6.7

Quality: 4.0

Yield: 0.0

Momentum: 0.5

Volatility: 1.3

1-Year Total Return ->

Inotiv

A-Score: 2.8/10

Value: 9.0

Growth: 3.1

Quality: 2.1

Yield: 0.0

Momentum: 2.0

Volatility: 0.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

11.18%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

4.18%

T2 Biosystems, Inc. - US89853L3024

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on TTOO

1.c. Company Highlights

Weak Momentum

Medium Volatility

Fairly Valued

Earnings Miss

Revenues Beats

More Volatile

Earnings Beats

Revenues Miss

Cheaper

Stable Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.11%)

6. Segments

Consumables

Expected Growth: 9.08%

Instruments

Expected Growth: 9.27%

Service

Expected Growth: 9.95%

Contribution

Expected Growth: 10.33%

Instrument Rentals

Expected Growth: 8.4%

7. Detailed Products

T2Bacteria Panel

T2Candida Panel

T2Resistance Panel

T2SARS-CoV-2 Panel

T2Dx Instrument

8. T2 Biosystems, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: T2 Biosystems, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.0$

Current Price

0.0$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA